Indeed, another study specifically involving patients with severe sepsis not only failed to demonstrate a mortality benefit of TGC in diabetic and non-diabetic patients but was prematurely terminated for safety reasons (there was a significantly increased rate of severe hypoglycemic events ≤ 40 mg/dL in the intensive insulin therapy group versus conventional therapy group: 17% and 4.1%, respectively, p < 0.001)44. The gene discussed is INS; the disease is Sepsis.